Bassi PF: BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol 11: 77-83, 2002.Bassi P.BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surgical Oncology . 2002
With BCG, which is the gold standard of treatment for high-risk non-muscle invasive bladder cancer, unfortunately, we have had shortages in the United States and worldwide. This is also driving trends that we observed, particularly in this study, with increasing use of intravesical gemcitabine a...
Insurance companies that transform the way they measure and predict the occurrence of risk during the current pandemic will, we believe, be much better positioned to succeed in times of future turmoil. But to do so, insurers must both increase their understanding of their customer base and make...
Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identify...
bcg.com.cn To expand the import control to coverfoodwithahigh potentialhealth risk, the Administration proposed that import requirements [...] legco.gov.hk legco.gov.hk 為擴大進口管制,以涵蓋具有較高潛在健康風險的食物,政府當局建議條 例草案下的規例應訂明進口規定。
CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-ri...
The FDA has accepted a Biologic License Application for Vicineum as a treatment option for patients with high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive non–muscle invasive bladder cancer (NMIBC), and granted it Priority Review, according to a press release issued by the drug develop...
“We are encouraged by this momentum following our recent announcement of first results from our Phase 3 BOND-003 study for patients with high-risk BCG-unresponsive NMIBC. CG Oncology looks forward to working with the FD...
Kamat AM,Colin PN.A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol . 2006Kamat, Dinney, A. M,Colin P. N.A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nature ...
Interim data for BOND-003 showed anti-tumor activity of cretostimogene grenadenorepvec as monotherapy in patients with high-risk BCG-unresponsive NMIBC. Based on a preliminary data cutoff on October 5, 2023, 66 pati...